Dr. Thomas Reske highlighted upper GI cancer advances, noting a 46% OS benefit with adjuvant nivolumab (Checkmate 577) and strong survival with FLOT+nivolumab (Matterhorn). Trastuzumab deruxtecan cut progression risk by 30% (Destiny 04). Claudin, CAR T, and antibody-drug conjugates show promise.